German Court Decision in ParkerVision v. Apple Infringement Case Awaits Validity Ruling
Jun 23, 2017 11:00 am UTC| Business
JACKSONVILLE, Fla., June 23, 2017 -- ParkerVision, Inc. (NASDAQ:PRKR), announced today that the Regional Court of Munich is holding its decision in the ParkerVision v. Apple case until after the German Federal Patent...
Jun 23, 2017 11:00 am UTC| Business
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced...
Jun 23, 2017 11:00 am UTC| Business
CAMBRIDGE, Mass., June 23, 2017 -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as...
Jun 23, 2017 11:00 am UTC| Business
MADRID, Spain, June 23, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced data...
Jun 23, 2017 11:00 am UTC| Business
MADRID, Spain, June 23, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, announced that results...
Alcobra Updates on its Review of Strategic Alternatives
Jun 23, 2017 11:00 am UTC| Business
TEL AVIV, Israel, June 23, 2017 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that its Board...
Jun 23, 2017 10:30 am UTC| Business
Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with “Double- or Triple-Hit” DLBCL With Additional Responders, Median Duration of Response Remains Greater than 7 Months Top-Line Data from SADAL...